Mednet Logo

Would you change treatment for denovo stage IV breast cancer Her 2 positive, ER positive in remission now with isolated brain metastasis?

The patient received THP and now is on maintenance HP when she developed CNS disease.
3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Huntsman Cancer Institute at the University of Utah
Answered on · Updated on

I would not change systemic treatment for such a patient if they have stable disease outside the brain. The intracranial disease should be treated with SRS or WBRT or surgery, as the case may be. With the various anti Her-2 treatment options in this setting, namely trastuzumab, pertuzumab, T-DM1 and...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · Stanford Health Care
Answered on

The TBCRC 022 phase II did have an impressive composite CNS ORR 49% in the cohort "3" with Neratinib and Xeloda as recently highlighted in JCO. The NALA trial will be presented in a few weeks at ASCO but in the 3rd Line HER2+ MBC setting. Unfortunately, the although isolated brain met is likely a ha...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · University of Iowa Holden Comprehensive Cancer Center
Answered on · Updated on

I agree with @Dr. First Last's approach. There is a risk of progression outside CNS in this case given new brain mets, One could continue same systemic therapy but considering small molecule inhibitors like Lapatinib or Neratinib concurrent with SRS could give better CNS control. These agents should...

Join for free or sign in to see the full answer